Eli Lilly CEO John Lechleiter (photo) hasn't budged from his vow not to pursue a megamerger, as many of the pharma's rivals have done. "We are not interested in a large-deal combination," the exec said at the Sanford C. Bernstein investor conference. However, Lilly is looking for deals. And while diversity is essential, Lilly will look to expansion in areas congruent with its animal- and human-health model, which includes companion diagnostics and drug delivery technology. Report